JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 4
Combined Treatment of Rectal Cancer Using Two-component Radiomodification with Neoadjuvant Radiation Therapy Together with a Chemotherapy
Yu.A. Barsukov1, S.I. Tkachev1, Z.Z. Mammadli1, V.A. Aliev1,
O.A. Vlasov2, N.D. Oltarzhevskaya3, M.A. Korovina3
1N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow, Russia
2Russian Scientific Center of Radiology and Nuclear Medicine, Ministry of Health of Russia, Moscow, Russia
3“Coletex” Ltd., Moscow, Russia
Contact person: Yu.A. Barsukov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: to evaluate the effectiveness of a “short” course of neoadjuvant radiation therapy using two radio modifiers with different mechanisms of radio-modulating action together with a drug therapy.
Material and methods: To increase the effectiveness of radiation therapy there was created a variant of combined treatment of patients with rectal cancer, using the concept of polyradiomodification. Two radio modifiers have been applied (local microwave hyperthermia and intrarectal Metronidazole administration as part of a polymer composition) together with neoadjuvant radiation therapy and oral administration of Capecitabine, followed by surgical intervention 4–6 weeks after the end of radiation therapy. For intrarectal delivery of Metronidazole to the tumor, a new medical device was created, which is a biopolymer composition in the form of a hydrogel with a Metronidazole substance physically immobilized in it (RF Patent No. 2007139304, 2007).
Results: The study included 520 patients, of whom 114 underwent a new variant of combined treatment with modulation of the effect of irradiation with two different radiomodifiers together with a drug therapy (group-1), 193 patients underwent only single-mode radiation therapy (group-2), and 213 patients underwent a combination of radiation therapy with local microwave hyperthermia (group-3). Toxic manifestations in group-1 was diagnosed in 38 (33,3 %) of 114 patients, general toxic manifestations of the III degree – in 13 (11,4 %) of 114. Postoperative complications in the group-1 was observed in 21 (18,4 %) of 114 patients, which was significantly less than in the group-2 and group-3, where they occurred in 78 (40,4 %) of 193 (p=0,0001) and in 78 (36,6 %) of 213 (p=0,0006). With a median follow-up of 54,6 months. relapses of cancer in the group-1 was not detected in any of 114 patients, which is significantly less than in the group-2, in which cancer relapses were diagnosed in 17 (8,8 %) of 193 patients (p=0,0011), and in the group-3, where they were detected in
10 (4,7 %) of 213 patients (p=0,0188). This made it possible to increase the number of sphincter-preserving operations performed in the group-1 to 84,2 %, which is significantly more compared to 53,4 % in the group-2 (p=0,00001) and 56,8 % in the group-3 (p=0,00001). It was also possible to significantly increase the rate of five-year relapse-free survival in the group-1 up to 82,9 % compared to 65,3 % at group-2 (p=0,01106) and 61,1 % at group-3 (p=0,00276).
Conclusion: The treatment option using polyradiomodification is effective in improving local antitumor control of the disease and increasing relapse-free survival rates compared to other combined treatment options.
Keywords: rectal cancer, combined treatment, radiomodifiers, therapeutic pathomorphosis, long-therm results
For citation: Barsukov YuA, Tkachev SI, Mammadli ZZ, Aliev VA, Vlasov OA, Oltarzhevskaya ND, Korovina MA. Combined Treatment of Rectal Cancer Using Two-component Radiomodification with Neoadjuvant Radiation Therapy Together with a Chemotherapy. Medical Radiology and Radiation Safety. 2022;67(4):69-73. (In Russian) DOI:10.33266/1024-6177-2022-67-4-69-73
References
1.Yarmonenko S.P. Polyradiomodification as a New Approach to Improving the Efficiency of Radiation Therapy of Tumors. Materialy Vsesoyuznoy Konferentsii Radiomodifikatory v Luchevoy Terapii Opukholey = Proceedings of the All-Union Conference Radiomodifiers in Radiation Therapy of Tumors. Obninsk, 8-10 December, 1982 g. Obninsk Publ., 1982. P. 126-127 (In Russian).
2. Materialy XI Syezda Rossiyskogo Soyuza Rektorov = Materials of the XI Congress of the Russian Union of Rectors. St. Petersburg, 26 April, 2018. St. Petersburg Publ., 2018 (In Russian).
3. Maleyeva K.P., Karimov N.A., Mulatov A.A., et al. Radiosensitivity of Tumors and Methods of Radiomodification. Mezhdunarodnyy studencheskiy nauchnyy vestnik = European Student Scientific Journal. 2018;2:22 (In Russian).
4. Boyko A.V., Daryalova S.L., Demidova L.V., et al. Radiomodifikatsiya pri Luchevoy Terapii Bolnykh so Zlokachestvennymi Opukholyami = Radio Modification in Radiation Therapy of Patients with Malignant Tumors. Guidelines. Moscow Publ., 1996. 11 p. (In Russian).
5. Barsukov I.A., Tkachev S.I., Nikolaev A.V., et al. Preoperative Thermoradiotherapy in the Combined Treatment of Rectal Tumors Is the Inferior Ampullar Segmento. Problems in Oncology. 1999;45;6:665-669.
6. Barsukov Yu.A., Tkachev S.I., Knysh B.I., et al. Сombined Treatment of Rectal Cancer Applying Preoperative Irradiation and Several Radiomodifiiers. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2008;53;2:25-31 (In Russian).
7. Barsukov Yu.A., Tkachev S.I., Knysh B.I., et al. Combined Treatment for Rectal Cancer Using Different Radiomodification Means. Voprosy onkologii = Problems in Oncology. 2008;54;3:350-353 (In Russian).
8. Barsukov Yu.A., Tkachev S.I., Knysh B.I., Mamedli Z.Z., et al. Combination Treatment of Rectal Cancer Using Polyradiomodification and Short Courses of Neoadjuvant Radiotherapy. Tazovaya Khirurgiya i Onkologiya = Pelvic Surgery and Oncology. 2019;9;3:34-45 (In Russian).
9. Barsukov Yu.A. Cancer of the Rectum and Anal Canal: Prospects for Combined Treatmen. Moscow Publ., 2019. P. 274-341. (In Russian).
10. Common Terminology Criteria for Adverse Events (CTCAE). U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute. Version 4.0. 2009.
11. Lavnikova G.A. Some Patterns of Radiation Pathomorphosis of Human Tumors and Their Practical Use. Vestnik AMN SSSR. 1976;6:13-19 (In Russian).
12. Dworak O., Keilholz L., Hoffmann A. Pathological Features of Rectal Cancer after Preoperative Radiochemotherapy. Int. J. Colorectal Dis. 1997;12;1:19-23.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 17.01.2022. Accepted for publication: 15.03.2022.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 4
Peculiarities of Radionuclide Diagnosis of Signal Lymph Nodes in Patients of Breast Cancer with Using of Radiopharmaceutical Based on the Gamma-Aluminum Oxide Labeled with 99mTc
A.A. Medvedeva, V.I. Chernov, R.V. Zelchan, O.D. Bragina,
A.N. Rуbina, E.Iu. Garbukov, A.V. Doroshenko,
N.A. Tarabanovskaya
Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia
Contact person: Anna Alexandrovna Medvedeva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To study the possibility of using [99mТс]-Al2O3 for the diagnosis of sentinel lymph nodes (SLN) in patients with breast cancer, to analyze the results obtained in comparison with a phytate colloid labeled with 99mTc.
Material and methods: The study included 86 patients with breast cancer. [99mTc]-phytate colloid (31 patients) and [99mТс]-Al2O3 (55 patients) were used as radiopharmaceutical.
Results: The optimal time interval between the injection of [99mТс]-Al2O3 and the acquisition of a scintigraphic image was determined to be 18-20 hours, when the maximum possible number of lymph nodes (LNs) with the most optimal level of radioactivity for their detection is visualized.
In the group of patients who were injected with [99mTc]-phytate colloid, SLN were visualized in 27 out of 31 patients, a total of 37 LNs were detected in this group. The median number of detected LNs in one patient was 1 [0–3], the intensity of accumulation of [99mTc]-phytate colloid according to single-photon emission computed tomography (SPECT) was 1.75% [0.5–4.3%], intraoperatively using gamma -probe – 2.95% [1.1–5.6%].
When [99mТс]-Al2O3 was used as radiopharmaceutical, SLNs were detected in 51 patients out of 55. In total, 111 LNs were detected in this group, the median number of detected LNs in one patient was 2 [0-6], the intensity of accumulation of [99mТс]-Al2O3 according to SPECT data – 6.1% [0.5–18.4%], intraoperatively – 7.2% [1.3–22.1%].
In the absence of radiopharmaceuticals accumulation in regional LNs (n=7 in total), 3 patients had total metastatic lesions of the SLN, in two of them other regional LNs were also affected by metastases.
Conclusion: A comparative analysis of the indices of two radiopharmaceuticals shows that studies with [99mТс]-Al2O3 are characterized by statistically significantly higher accumulation rates in the SLN compared with [99mTc]-phytate colloid. The number of detected LNs when using [99mТс]-Al2O3 was also higher than in the group with [99mTc]-phytate colloid. As a result, when [99mТс]-Al2O3 is used, the method is characterized by higher sensitivity in detecting SLN (94.5%).
Keywords: 99mТс, gamma alumina, sentinel lymph node, breast cancer
For citation: Medvedeva AA, Chernov VI, Zelchan RV, Bragina OD, Rуbina AN, Garbukov EIu, Doroshenko AV, Tarabanovskaya NA. Peculiarities of Radionuclide Diagnosis of Signal Lymph Nodes in Patients of Breast Cancer with Using of Radiopharmaceutical Based on the Gamma-Aluminum Oxide Labeled with 99mTc. Medical Radiology and Radiation Safety. 2022;67(4):74-79. DOI: 10.33266/1024-6177-2022-67-4-74-79
References
1. Benson J.R., Della Rovere G.Q. Axilla Management Consensus Group. Management of the Axilla in Women with Breast Cancer. Lancet Oncol. 2007;8:331–348.
2. Krag D.N., Anderson S.J., Julian T.B., et al. Sentinel-Lymph-Node Resection Compared with Conventional Axillary-Lymph-Node Dissection in Clinically Node-Negative Patients with Breast Cancer: Overall Survival Findings from the NSABP B-32 Randomised Phase 3 Trial. Lancet Oncol. 2010;11;10:908-909.
3. Moo T.A., Sanford R., Dang C., Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018;13;3:339–354.
4. Plichta J.K. Breast Cancer Prognostic Staging and Internal Mammary Lymph Node Metastases: a Brief Overview. Chin. Clin. Oncol. 2019;8:1–11.
5. Afanasyeva K.V., Petrovskiy A.V., Nechushkin M.I., Shiryayev S.V., et al. Life Quality Assessment in Breast Cancer Patientes after an Axillary Lymph Node Dissection Comparing with a Sentinel Lymph Node Biopsy. Vestnik RONTS im. N. N. Blokhina RAMN = Journal of N. N. Blokhin Russian Cancer Research Center. 2017;28;1–2:45–52 (In Russ.).
6. Krivorotko P.V., Kanayev S.V., Semiglazov V.F., Novikov S.N., et al. Methodological problems of sentinel lymph node biopsy in patients with breast cancer. Voprosy Onkologii = Problems in Oncology. 2015;61;3:418-423 (In Russ.).
7. Vaz S.C., Oliveira F., Herrmann K., Veit-Haibach P. Nuclear Medicine and Molecular Imaging Advances in the 21st Century. Br. J. Radiol. 2020;93;1110:20200095.
8. Chernov V.I., Dudnikova E.A., Zelchan R.V., Kravchuk T.L. et al. The First Experience of Using 99mTc-1-Thio-d-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Siberian Journal of Oncology. 2018;17;4:81-87.
9. Titskaya A.A., Chernov V.I., Slonimskaya Ye.M., Sinilkin I.G. Comparison of 99mTc-MIBI Mammoscintigraphy Findings in Planar and Tomographic Images. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2008;53;5:51-60 (In Russ.).
10. Chernov V.I., Zelchan R.V., Titskaya A.A., Sinilkin I.G., et al. Gamma Scintigraphy with 99mTc-MIBI in the Complex Diagnostics and Assessment of Neoadjuvant Chemotherapy Efficacy in Laryngeal and Laryngopharyngeal Cancers. Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2011;56;2:38-43 (In Russ.).
11. Zavadovskaya V.D., Kurazhov A.P., Kilina O.YU., Choynzonov Ye.L., et al. Differential Diagnostics Inflammatory and Neoplastic Processes of Locomotor Sistem with 199Tl-Сhloride Scintigraphy. Meditsinskaya Vizualizatsiya = Medical Visualization. 2009;4:55-65 (In Russ.).
12. Zhang J.J., Zhang W.C., An C.X., Li X.-M., Ma L. Comparative Research on 99mTc-Rituximab and 99mTc-Sulfur Colloid in Sentinel Lymph Node Imaging of Breast Cancer. BMC Cancer. 2019;1:956.
13. Unkart J.T., Proudfoot J., Wallace A.M. Outcomes of «One-Day» vs «Two-Day» Injection Protocols Using Tc-99m Tilmanocept for Sentinel Lymph Node Biopsy in Breast Cancer. Breast J. 2018;24;4:526–530.
14. Chernov V., Sinilkin I., Choynzonov E., Chijevskaya S. et al. Comparative Evaluation of 99mTс-Al2O3 and 99mTс-Fitat Nanocolloids for Sentinel Lymph Nodes Visualization in Patients with Cancer of Larynx and Hypopharynx. Eur. J. Nucl. Med. Mol. Imaging. 2015;42;S1:704.
15. Sinilkin I., Chernov V., Zelchan R., Titskaya A.A., Skuridin V. Clinical Investigaition of Nanocolloid 99mTс-Al2O3 for Sentinel Lymph Nodes Visualization. Eur. J. Nucl. Med. Mol. Imaging. 2014;41;(Suppl 2):518.
16. Agrawal A, Civantos FJ, Brumund KT, Chepeha DB et al. 99m Tc-Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-Institutional Trial. Ann. Surg. Oncol. 2015;11:3708–3715.
17. Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zelchan R.V., et al. Experience in the Development of Innovative Radiopharmaceuticals at the Tomsk Research Institute of Oncology. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2015;Appendix2:45-47 (In Russ.).
18. Persico M.G., Lodola L., Buroni F.E., Morandotti M., et al. (99m)Tc-Human Serum Albumin Nanocolloids: Particle Sizing and Radioactivity Distribution. J. Labelled Comp. Radiopharm. 2015;58;9:376-382.
19. Yararbas U., Argon A.M., Yeniay L., Zengel B., Kapkaç M. The Effect of Radiocolloid Preference on Major Parameters in Sentinel Lymph Node Biopsy Practice in Breast Cancer. Nucl. Med. Biol. 2010;37;7:805-810.
20. Jimenez I.R., Roca M., Vega E., García M.L., et al. Particle Sizes of Colloids to Be Used in Sentinel Lymph Node Radio Localization. Nucl. Med. Commun. 2008;29;2:166–172.
21. Skuridin V.S., Stasyuk Ye.S., Varlamova N.V., Rogov A.S., et al. Obtaining a new nanocolloidal radiopharmaceutical based on aluminum oxide. Izvestiya Tomskogo Politekhnicheskogo Universiteta. Inzhiniring Georesursov = Bulletin of the Tomsk Polytechnic University. Geo Assets Engineering. 2013;323;3:33–37 (In Russ.).
22. Skuridin V.S., Chernov V.I., Varlamova N.V., Nesterov Ye.A., et al. Study of Functional Fitness Radiopharmaceuticals "Nanocolloids,99mTс-Al2O3" for Scintigraphic and Intraoperative Identification of "Sentinel" Lymph Nodes. Diagnosticheskaya i Interventsionnaya Radiologiya = Diagnostic and Interventional Radiology. 2015. № 3. С. 76–80 (In Russ.).
23. Cheng G., Kurita S., Torigian D.A., Alavi A. Current Status of Sentinel Lymph-Node Biopsy in Patients with Breast Cancer. Eur. J. Nucl. Med. Mol. Imaging. 2011;38:562-575.
24. Kanayev S.V., Novikov S.N., Krivorotko P.V., Semiglazov V.F., et al. Methodological Issues of Sentinel Lymph Nodes Biopsy in Patients with Breast Cancer. Voprosy onkologii = Problems in Oncology. 2013. Т.59, № 2. С. 90-94 (In Russ.).
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 11.04.2022. Accepted for publication: 11.05.2022
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 4
Research of Dosimetric Characteristics of Human Hair Depending on the Content of Melanine
D.V. Ivanov1,3, D.R. Baitimirov1, S.F. Konev1, E.K. Vasilenko2,
E.E. Aladova2
1B.N. Yeltsin Urals Federal University, Yekaterinburg, Russia
2Southern Urals Biophysics Institute, Ozersk, Russia
3M.N. Mikheev Institute of Metal Physics, Ural Branch of the RAS, Yekaterinburg, Russia
Contact person: Aladova Е.Е., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Investigation of paramagnetic properties of radiation-induced centers that occur when hair samples are irradiated with ionizing radiation, depending on the color of the sample.
Material and methods: A Bruker Elexsys E580 electron paramagnetic resonance spectrometer was used. To improve the signal-to-noise ratio, the spectrum was recorded with three accumulations with a constant scan time equal to one minute. Measurements were made using a highly sensitive rectangular Bruker SuperHighQ resonator. For irradiation of samples, the linear electron accelerator UELR-10-10С2 of the innovation and implementation center for radiation sterilization of the Urals Federal University (Institute of Physics and technology) was used.
Results: Research of the EPR signal parameters of the melanin in hair samples of different colors (black, brown, red and gray with different degrees of pigmentation) showed that the intensity of the EPR signal varies depending on the hair color. The higher the radiation sensitivity of the hair, the lighter the color of the hair. The melanin signal, which is the background for the radiation-induced signal, increases with increasing intensity of hair color.
Key words: dosimetry, electron paramagnetic resonance, melanin, radiation sensitivity, human hairs
For citation: Ivanov DV, Baitimirov DR, Konev SF, Vasilenko EK, Aladova EE. Research of Dosimetric Characteristics of Human Hair Depending on the Content of Melanine. Medical Radiology and Radiation Safety. 2022;67(4):89-95. DOI: 10.33266/1024-6177-2022-67-4-89-95
References
1. Ivanov D.V., Baytimirov D.R., Konev S.F., Aladova Ye.Ye., Vasilenko Ye.K. Possibility of Various Materials to Be Used for EPR Dosimetry in Cases of Emergency Radiation Exposure. Voprosy Radiatsionnoy Bezopasnosti = Journal of Radiation Safety Issues. 2018;3:75-81 (In Russ).
2. Gordy W., Ard W.B., Shieids H. Proc. Nat. Acad. Sci. 1955;41:983-996. DOI: 10.1073/pnas.41.11.983.
3. Chernova O.F., Tselikova T.N. Atlas of Hair of Mammals. Tonkaya Struktura Ostevykh Volos i Igl v Skaniruyushchem Elektronnom Mikroskope = The Fine Structure of Guard Hairs and Needle in a Scanning Electron Microscope. Moscow, Tovarishchestvo Nauchnykh Izdaniy KMK Publ., 2004 (In Russ).
4. Goldstein B., Gibson J., Henderson R., et al. Biological Markers in Environmental Health Research. Environ. Health Persp. 1987;74:3-9. DOI: 10.1289/ehp.87743.
5. Jaakkola M.S., Samet J.M. Occupational Exposure to Environmental Tobacco Smoke and Health Risk Assessment. Environ. Health Persp. 1999;107;6:829-835. DOI: 10.1289/ehp.99107s6829.
6. Klein J., Koren G. Hair Analysis–a Biological Marker for Passive Smoking in Pregnancy and Childhood. Hum. Exp. Toxicol. 1999;18:279-282. DOI: 10.1191/096032799678840048.
7. Girod C., Staub C. Acetylcodeine as a Marker of Illicit Heroin in Human Hair: Method Validation and Results of a Pilot Study. J. Anal. Toxicol. 2001;25:106-111. DOI: 10.1093/jat/25.2.106.
8. Cizdziel J.V., Gerstenberger S. Determination of Total Mercury in Human Hair and Animal Fur by Combustion Atomic Absorption Spectrometry. Talanta. 2004;64:918-921. DOI: 10.1016/j.talanta.2004.04.013.
9. Revich B.A. Lead in Hair and Urine of Children and Adults from Industrialized Areas. Arch. Environ. Health. 1994;49:59-62. DOI: 10.1080/00039896.1994.9934416.
10. Bustueva K.A., Revich B.A., Bezpalko L.E. Cadmium in the Environment of Three Russian Cities and in Human Hair and Urine. Arch. Environ. Health. 1994;49:284-288. DOI: 10.1080/00039896.1994.9937481.
11. Daniel K.G., Harbach R.H., Guida W.C., Dou Q.P. Copper Storage Diseases: Menkes, Wilsons, and Cancer. Front. Biosci. 2004;9:2652-2662. DOI: 10.2741/1424.
12. Di Donato P., Napolitano A. 1,4-Benzothiazines as Key Intermediates in the Biosynthesis of Red Hair Pigment Pheomelanins. Pigm. Cell Res. 2003;16:532-539. DOI: 10.1034/j.1600-0749.2003.00085.x.
13. Greco G., Panzella L., Verotta L., d’Ischia M., Napolitano A. Uncovering the Structure of Human Red Hair Pheomelanin: Benzothiazolylthiazinodihydroisoquinolines as Key Building Blocks. J. Nat. Prod. 2011;74:675-682. DOI: 10.1021/np100740n.
14. Costin G.-E., Hearing V.J. Human Skin Pigmentation: Melanocytes Modulate Skin Color in Response to Stress. FASEB J. 2007;21:976-994. DOI: 10.1096/fj.06-6649rev.
15. Sealy R.C., Hyde J.S., Felix C.C., Menon I.A., Prota G. Eumelanins and Pheomelanins: Characterization by Electron Spin Resonance Spectroscopy. Science. 1982;217;4559:545-547. DOI: 10.1126/science.6283638.
16. Chikvaidze E., Khachatryan I. ESR Study of Photoinduced Free Radicals by Visible Light in Hair and the Effects of Ascorbic Acid (Vitamin C). Int. J. Cosmet. Sci. 2011;33:322-327. DOI: 10.1111/j.1468-2494.2010.00628.x.
17. Şeyda Çolak, Turan Özbey. An ESR Study on Biological Dosimeters: Human Hair. Rad. Meas. 2011;46;5:465-472. DOI: /10.1016/j.radmeas.2010.12.002.
18. Trevedi A., Greenstock C.L. Use of Sugars and Hair for ESR Emergency Dosimetry. Appl. Radiat. Isot. 1993;44:85-90. DOI: 10.1016/0969-8043(93)90201-k.
19. Tepe Çam S., Polat M., Seyhan N. The Use of Human Hair as a Biodosimeter. Appl. Radiat. Isot. 2014;94:272-281. DOI: 10.1016/j.apradiso.2014.08.021.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The work was carried out within the framework of state contract No. 11.310.19.2 on the topic “Improving the provision of emergency preparedness and response of the South Ural Regional Medical and Dosimetric Emergency Center in the event of radiation accidents” (code “Response-19”), funded by the Federal Medical and Biological Agency of Russia. EPR measurements were partly carried out within the framework of the state order of the Ministry of Education and Science of Russia (topic "Spin", No. AAAA-A18-118020290104-2).
Contribution. Article was prepared with equal participation of the authors
Article received: 15.03.2022.
Accepted for publication: 23.04.2022
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 4
X-ray and Radionuclide Imaging in the Diagnosis
of ACTH-Producing Neuroendocrine Tumors
O.O. Golounina1, K.Yu. Slashchuk2, A.V. Khairieva2, N.V. Tarbaeva2,
M.V. Degtyarev2, Zh.E. Belaya2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia
2The National Medical Research Center for Endocrinology, Moscow, Russia
Contact person: Golounina Olga Olegovna, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Ectopic ACTH syndrome caused by excessive production of adrenocorticotropic hormone (ACTH) by a neuroendocrine tumor (NET) is an extremely rare disease, the main manifestation of which is pronounced hypercortisolism. In order to avoid the development of life-threatening complications and disability of the patient, timely topical diagnosis and rapid decision-making on further management tactics are necessary. The problem of the diagnosis of NET and differential diagnosis with other formations remains relevant and one of the little-studied. Despite the existing wide arsenal of methods of conventional diagnostics, functional and receptor imaging, the source of the disease remains unidentified in about 20% of patients. This article discusses the modern possibilities of NET visualization using conventional and radionuclide imaging methods, demonstrates the diagnostic capabilities of somatostatin-receptor scintigraphy and single-photon emission computed tomography combined with computed tomography (SPECT/CT) and combined positron emission and computed tomography (PET/CT) in the visualization of NET producing ACTH, and analyzes existing radiopharmaceuticals.
Keywords: multislice computed tomography, somatostatin-receptor scintigraphy, SPECT/CT, PET/CT, ectopic ACTH syndrome; neuroendocrine tumor (NET)
For citation: Golounina OO, Slashchuk KYu, Khairieva AV, Tarbaeva NV, Degtyarev MV, Belaya ZhE. X-ray and Radionuclide Imaging in the Diagnosis of ACTH-Producing Neuroendocrine Tumors. Medical Radiology and Radiation Safety. 2022;67(4):80-88. DOI: 10.33266/1024-6177-2022-67-4-80-88
References
1. Ilias I., Torpy D.J., Pacak K., Mullen N., Wesley R.A., Nieman L.K. Cushing’s Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years’ Experience at the National Institutes of Health. J. Clin. Endocrinol Metab. 2005;90;8:4955–4962. doi: 10.1210/jc.2004-2527.
2. Голоунина О.О., Белая Ж.Е., Рожинская Л.Я., Марова Е.И., Пикунов М.Ю., Хандаева П.М. и др. Клинико-лабораторная характеристика и результаты лечения пациентов с АКТГ-продуцирующими нейроэндокринными опухолями различной локализации // Терапевтический архив. 2021. Т.93, № 10. С. 1171–1178. [Golounina O.O., Belaya Zh.Ye., Rozhinskaya L.Ya., Marova Ye.I., Pikunov M.Yu., Khandayeva P.M., et al. Clinical and Laboratory Characteristics and Results of Treatment of Patients with ACTH-Producing Neuroendocrine Tumors of Various Localization. Terapevticheskiy Arkhiv = Therapeutic Archive. 2021;93;10:1171–1178 (In Russ.)]. doi: 10.26442/00403660.2021.10.201102.
3. Isidori A.M., Sbardella E., Zatelli M.C., Boschetti M., Vitale G., Colao A., et al. Conventional and Nuclear Medicine Imaging in Ectopic Cushing’s Syndrome: A Systematic Review. The Journal of Clinical Endocrinology & Metabolism. 2015;100;9:3231–3244. doi: 10.1210/JC.2015-1589.
4. Zemskova M.S., Gundabolu B., Sinaii N., Chen C.C., Carrasquillo J.A., Whatley M., et al. Utility of Various Functional and Anatomic Imaging Modalities for Detection of Ectopic Adrenocorticotropin-Secreting Tumors. J. Clin. Endocrinol Metab. 2010;95;3:1207–1219. doi: 10.1210/jc.2009-2282.
5. Kwekkeboom D.J., Kam B.L., van Essen M., Teunissen J.J.M., van Eijck C.H.J., Valkema R., et al. Somatostatin Receptor-Based Imaging and Therapy of Gastroenteropancreatic Neuroendocrine Tumors. Endocrine-Related Cancer. 2010;17;1:53–73. doi: 10.1677/ERC-09-0078.
6. Bhanat E., Koch C.A., Parmar R., Garla V., Vijayakumar V. Somatostatin Receptor Expression in Non-Classical Locations – Clinical Relevance? Rev. Endocr. Metab. Disord. 2018;19;2:123–132. doi: 10.1007/s11154-018-9470-3.
7. Koopmans K.P., Neels O.N., Kema I.P., Elsinga P.H., Links T.P., de Vries E.G.E., Jager P.L. Molecular Imaging in Neuroendocrine Tumors: Molecular Uptake Mechanisms and Clinical Results. Crit. Rev. Oncol. Hematol. 2009;71;3:199–213. doi: 10.1016/j.critrevonc.2009.02.009.
8. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., et al. Somatostatin Receptor Scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-Octreotide: the Rotterdam experience with more than 1000 Patients. Eur. J. Nucl. Med. 1993;20;8:716–731. doi: 10.1007/BF00181765.
9. Jamar F., Fiasse R., Leners N., Pauwels S. Somatostatin Receptor Imaging with Indium-111-Pentetreotide in Gastroenteropancreatic Neuroendocrine Tumors: Safety, Efficacy and Impact on Patient Management. J. Nucl. Med. 1995;36;4:542–549.
10. Raderer M., Kurtaran A., Leimer M., Angelberger P., Niederle B., Vierhapper H., et al. Value of Peptide Receptor Scintigraphy Using 123I-Vasoactive Intestinal Peptide and 111In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998. J. Clin. Oncol. 2000;18;6:1331–1336. doi: 10.1200/JCO.2000.18.6.1331.
11. Binderup T., Knigge U., Loft A., Mortensen J., Pfeifer A., Federspiel B., et al. Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123 I-MIBG Scintigraphy, and 18 F-FDG PET. J. Nucl. Med. 2010;51;5:704–712. doi: 10.2967/jnumed.109.069765.
12. Рыжкова Д.В., Тихонова Д.Н., Гринева Е.Н. Методы ядерной медицины в диагностике нейроэндокринных опухолей // Сибирский онкологический журнал. 2013. № 6. С. 56–63. [Ryzhkova D.V., Tikhonova D.N., Grineva Ye.N. Nuclear Medicine Technology for Diagnosis of Neuroendocrine Tumors. Siberian Journal of Oncology. 2013;6:56–63 (In Russ.)].
13. Sundin A. Novel Functional Imaging of Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America. 2018;47;3:505–523. doi: 10.1016/j.ecl.2018.04.003.
14. Слащук К.Ю., Румянцев П.О., Дегтярев М.В., Серженко С.С., Баранова О.Д., Трухин А.А., Сирота Я.И. Молекулярная визуализация нейроэндокринных опухолей при соматостатин-рецепторной сцинтиграфии (ОФЭКТ/КТ) с 99mTc-Тектроитидом. Медицинская радиология и радиационная безопасность // 2020. Т.65, № 2. С. 44–49. [Slashchuk K.Yu., Rumyantsev P.O., Degtyarev M.V., Serzhenko S.S., Baranova O.D., Trukhin A.A., Sirota Ya.I. Molecular Imaging of Neuroendocrine Tumors by Somatostatin-Receptor Scintigraphy (SPECT/CT) with 99mTc-Tektrotyd. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2020;65;2:44–49 (In Russ)]. doi: 10.12737/1024-6177-2020-65-2-44-49.
15. Young J., Haissaguerre M., Viera-Pinto O., Chabre O., Baudin E., Tabarin A. Management of Endocrine Disease: Cushing’s Syndrome Due to Ectopic ACTH Secretion: an Expert Operational Opinion. Eur. J.. Endocrinol 2020;182;4:29–58. doi: 10.1530/EJE-19-0877.
16. Kaltsas G., Korbonits M., Heintz E., Mukherjee J.J., Jenkins P.J., Chew S.L., et al. Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors. J. Clin. Endocrinol Metab. 2001;86;2:895–902. doi: 10.1210/jcem.86.2.7194.
17. Ezziddin S., Logvinski T., Yong-Hing C., Ahmadzadehfar H., Fischer H.-P., Palmedo H., et al. Factors Predicting Tracer Uptake in Somatostatin Receptor and MIBG Scintigraphy of Metastatic Gastroenteropancreatic Neuroendocrine Tumors. J. Nucl. Med. 2006;47;2:223–233.
18. Virgolini I., Ambrosini V., Bomanji J.B., Baum R.P., Fanti S., Gabriel M., et al. Procedure Guidelines for PET/CT Tumour Imaging with 68Ga-DOTA-Conjugated Peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging. 2010;37;10:2004–2010. doi: 10.1007/s00259-010-1512-3.
19. Bodei L., Ambrosini V., Herrmann K., Modlin I. Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies. J. Nucl. Med. 2017;58;11:1718–1726. doi: 10.2967/jnumed.116.186361.
20. Reubi J.C., Schär J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., Mäcke H.R. Affinity Profiles for Human Somatostatin Receptor Subtypes SST1-SST5 of Somatostatin Radiotracers Selected for Scintigraphic and Radiotherapeutic Use. Eur. J. Nucl. Med. 2000;27;3:273–282. doi: 10.1007/s002590050034.
21. Poeppel T.D., Binse I., Petersenn S., Lahner H., Schott M., Antoch G., et al. 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors. J. Nucl. Med. 2011;52;12:1864–1870. doi: 10.2967/jnumed.111.091165.
22. Geijer H., Breimer L.H. Somatostatin Receptor PET/CT in Neuroendocrine Tumours: Update on Systematic Review and Meta-Analysis. Eur. J. Nucl. Med. Mol. Imaging. 2013;40;11:1770–1780. doi: 10.1007/s00259-013-2482-z.
23. Sadowski S.M., Neychev V., Millo C., Shih J., Nilubol N., Herscovitch P., et al. Prospective Study of 68 Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. JCO. 2016;34;6:588–596. doi: 10.1200/JCO.2015.64.0987.
24. Gabriel S., Garrigue P., Dahan L., Castinetti F., Sebag F., Baumstark K., et al. Prospective Evaluation of 68 Ga-DOTATATE PET/CT in Limited Disease Neuroendocrine Tumours and/or Elevated Serum Neuroendocrine Biomarkers. Clin. Endocrinol. 2018;89;2:155–163. doi: 10.1111/cen.13745.
25. Bergeret S., Charbit J., Ansquer C., Bera G., Chanson P., Lussey-Lepoutre C. Novel PET Tracers: Added Value for Endocrine Disorders. Endocrine. 2019;64;1:14–30. doi: 10.1007/s12020 -019-01895-z.
26. Skoura E., Michopoulou S., Mohmaduvesh M., Panagiotidis E., Al Harbi M., Toumpanakis C., et al. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. J. Nucl. Med. 2016;57;1:34–40. doi: 10.2967/jnumed.115.166017.
27. Deppen S.A., Blume J., Bobbey A.J., Shah C., Graham M.M., Lee P., et al. 68Ga-DOTATATE Compared with 111 In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J. Nucl. Med. 2016;57;6:872–878. doi: 10.2967/jnumed.115.165803.
28. Treglia G., Castaldi P., Rindi G., Giordano A., Rufini V. Diagnostic Performance of Gallium-68 Somatostatin Receptor PET and PET/CT in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumours: a Meta-Analysis. Endocrine. 2012;42;1:80–87. doi: 10.1007/s12020-012-9631-1.
29. Mojtahedi A., Thamake S., Tworowska I., Ranganathan D., Delpassand E.S. The Value of 68Ga-DOTATATE PET/CT in Diagnosis and Management of Neuroendocrine Tumors Compared to Current FDA Approved Imaging Modalities: a Review of Literature. Am. J. Nucl. Med. Mol. Imaging. 2014;4;5:426–434.
30. Johnbeck C.B., Knigge U., Kjær A. PET Tracers for Somatostatin Receptor Imaging of Neuroendocrine Tumors: Current Status and Review of the Literature. Future Oncol. 2014;10;14:2259–2277. doi: 10.2217/fon.14.139.
31. Haug A.R., Cindea-Drimus R., Auernhammer C.J., Reincke M., Beuschlein F., Wängler B., et al. Neuroendocrine Tumor Recurrence: Diagnosis with 68Ga-DOTATATE PET/CT. Radiology. 2014;270;2:517–525. doi: 10.1148/radiol.13122501.
32. Wannachalee T., Turcu A.F., Bancos I., Habra M.A., Avram A.M., Chuang H.H., et al. The Clinical Impact of [68 Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumours. Clin. Endocrinol (Oxf). 2019;91;2:288–294. doi: 10.1111/cen.14008.
33. Goroshi M.R., Jadhav S.S., Lila A.R., Kasaliwal R., Khare S., Yerawar C.G., et al. Comparison of 68Ga-DOTANOC PET/CT and Contrast-Enhanced CT in Localisation of Tumours in Ectopic ACTH Syndrome. Endocr Connect. 2016;5;2:83–91. doi: 10.1530/EC-16-0010.
34. Karageorgiadis A.S., Papadakis G.Z., Biro J., Keil M.F., Lyssikatos C., Quezado M.M., et al. Ectopic Adrenocorticotropic Hormone and Corticotropin-Releasing Hormone Co-Secreting Tumors in Children and Adolescents Causing Cushing Syndrome: A Diagnostic Dilemma and How to Solve It. The Journal of Clinical Endocrinology & Metabolism. 2015;100;1:141–148. doi: 10.1210/jc.2014-2945.
35. Sathyakumar S., Paul T.V., Asha H.S., Gnanamuthu B.R., Paul M.J., Abraham D.T., et al. Ectopic Cushing Syndrome: A 10-Year Experience from a Tertiary Care Center in Southern India. Endocrine Practice. 2017;23;8:907–914. doi: 10.4158/EP161677.OR.
36. Özkan Z.G., Kuyumcu S., Balköse D., Ozkan B., Aksakal N., Yılmaz E., et al. The Value of Somatostatin Receptor Imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH Producing Tumors. Mol. Imaging Radionucl Ther. 2013;22;2:49–55. doi: 10.4274/Mirt.69775.
37. Kakade H.R., Kasaliwal R., Jagtap V.S, Bukan A., Budyal S.R., Khare S., et al. Ectopic ACTH-Secreting Syndrome: A Single-Center Experience. Endocrine Practice. 2013;19;6:1007–1014. doi: 10.4158/EP13171.OR.
38. Varlamov E., Hinojosa-Amaya J.M., Stack M., Fleseriu M. Diagnostic Utility of Gallium-68-Somatostatin Receptor PET/CT in Ectopic ACTH-Secreting Tumors: a Systematic Literature Review and Single-Center Clinical Experience. Pituitary. 2019;22;5:445–455. doi: 10.1007/s11102-019-00972-w.
39. Ceccato F., Cecchin D., Gregianin M., Ricci G., Campi C., Crimì F., et al. The Role of 68Ga-DOTA Derivatives PET-CT in Patients with Ectopic ACTH Syndrome. Endocr Connect. 2020:EC-20-0089.R1. doi: 10.1530/EC-20-0089.
40. Liu Q., Zang J., Yang Y., Ling Q., Wu H., Wang P., et al. Head-to-Head Comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Localizing Tumors with Ectopic Adrenocorticotropic Hormone Secretion: a Prospective Study. Eur. J. Nucl. Med. Mol. Imaging. 2021;48;13:4386–4395. doi: 10.1007/s00259-021-05370-8.
41. Davi’ M.V., Salgarello M., Francia G. Positive (68)Ga-DOTATOC-PET/CT after Cortisol Level Control During Ketoconazole Treatment in a Patient with Liver Metastases from a Pancreatic Neuroendocrine Tumor and Ectopic Cushing Syndrome. Endocrine. 2015;49;2:566–567. doi: 10.1007/s12020-014-0391-y.
42. De Bruin C., Hofland L.J., Nieman L.K., van Koetsveld P.M., Waaijers A.M., Sprij-Mooij D.M., et al. Mifepristone Effects on Tumor Somatostatin Receptor Expression in Two Patients with Cushing’s Syndrome Due to Ectopic Adrenocorticotropin Secretion. J. Clin. Endocrinol Metab. 2012;97;2:455–462. doi: 10.1210/jc.2011-1264.
43. Balogova S., Talbot J.-N., Nataf V., Michaud L., Huchet V., Kerrou K., Montravers F. 18F-Fluorodihydroxyphenylalanine vs Other Radiopharmaceuticals for Imaging Neuroendocrine Tumours According to their Type. Eur. J. Nucl. Med. Mol. Imaging. 2013;40;6:943–966. doi: 10.1007/s00259-013-2342-x.
44. Mach R.H., Dehdashti F., Wheeler K.T. PET Radiotracers for Imaging the Proliferative Status of Solid Tumors. PET Clin. 2009;4;1:1–15. doi: 10.1016/j.cpet.2009.04.012.
45. Deng S., Zhang W., Zhang B., Chen Y., Li J., Wu Y. Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis. PLoS ONE. 2015;10;6:e0129028. doi: 10.1371/journal.pone.0129028.
46. Hindié E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017;7;5:1159–1163. doi: 10.7150/thno.19588.
47. Adams S., Baum R., Rink T., Schumm-Dräger P.M., Usadel K.H., Hör G. Limited Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for the Imaging of Neuroendocrine Tumours. Eur. J. Nucl. Med. 1998;25;1:79–83. doi: 10.1007/s002590050197.
48. Treglia G., Giovanella L., Lococo F. Evolving Role of PET/CT with Different Tracers in the Evaluation of Pulmonary Neuroendocrine Tumours. Eur. J. Nucl. Med. Mol. Imaging. 2014;41;5:853–855. doi: 10.1007/s00259-014-2695-9.
49. Santhanam P., Taieb D., Giovanella L., Treglia G. PET Imaging in Ectopic Cushing Syndrome: a Systematic Review. Endocrine. 2015;50;2:297–305. doi: 10.1007/s12020-015-0689-4.
50. Xu H., Zhang M., Zhai G., Zhang M., Ning G., Li B. The Role of Integrated 18F-FDG PET/CT in Identification of Ectopic ACTH Secretion Tumors. Endocr. 2009;36;3:385–391. doi: 10.1007/s12020-009-9247-2.
51. Bahri H., Laurence L., Edeline J., Leghzali H., Devillers A., Raoul J.-L., et al. High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: a Long-Term Evaluation. J. Nucl. Med. 2014;55;11:1786–1790. doi: 10.2967/jnumed.114.144386.
52. Panagiotidis E., Bomanji J. Role of 18F-Fluorodeoxyglucose PET in the Study of Neuroendocrine Tumors. PET Clinics 2014;9;1:43–55. doi: 10.1016/j.cpet.2013.08.008.
53. Hofman M.S., Lau W.F.E., Hicks R.J. Somatostatin Receptor Imaging with 68 Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation. RadioGraphics. 2015;35;2:500–516. doi: 10.1148/rg.352140164.
54. Ambrosini V., Kunikowska J., Baudin E., Bodei L., Bouvier C., Capdevila J., et al. Consensus on Molecular Imaging and Theranostics in Neuroendocrine Neoplasms. European Journal of Cancer. 2021;146:56–73. doi: 10.1016/j.ejca.2021.01.008.
55. Kunikowska J., Ambrosini V., Herrmann K. EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours-the consensus in a nutshell. Eur. J. Nucl. Med. Mol. Imaging. 2021;48;5:1276–1277. doi: 10.1007/s00259-021-05262-x.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. Research supported by the Russian Science Foundation (RSF grant 19-15-00398-P)
Contribution. Article was prepared with equal participation of the authors
Article received: 20.04.2022. Accepted for publication: 24.06.2022
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 4
Anti-Glomerular Basement Membrane Antibody Disease
with Mild Kidney Failure and Without Progression of Lung Pathology: Case Report
Sheikh Zh.V. 1,2, Nikolaev E.V.1, Gazaryan Ya.R.1, Safonova T.D.1, Zakharova E.V. 1,2
1Russian Medical Academy of Continued Professional Education, Moscow, Russia.
2S.P. Botkin’s City Clinical Hospital, Moscow, Russia.
Contact person: Zhanna V. Sheikh; E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Anti-GBM antibody disease (Goodpasture syndromee) is a rare immunecomlpex vasculitis, affecting small vessels, and characterized by rapidly progressive glomerulonephritis and alveolitis. Causative mechanism is defined by the hyperproduction of autoantibodies against the α3-chain of type IV collagen (Goodpasture antigen) with immune complex formation on the glomerular and alveolar basement membrane. Typically patients with fnti-GBM antibody disease present with rapidly progressive (crescentic) glomerulonephritis, more than in half of cases associated with alveolar hemorrhage. Cases of Anti-GBM antibody disease with atypical clinical presentation have been reported.
We report a case of atypical clinical presentation anti-GBM antibody disease with mild renal damage and slow progression of pulmonary involvement. Main CT signs were multiple centrilobular ground glass nodules.
This case report demonstrates that CT with disseminated pulmonary process associated with even mild kidney involvement in patients with high anti-GBM antibodies titers gives a clue to the diagnosis of anti-GBM antibody disease.
Keywords: Goodpasture syndrome, anti-GBM antibody disease, glomerulonephritis, computed tomography, case report.
For citation: Sheikh ZhV, Nikolaev EV, Gazaryan YaR, Safonova TD, Zakharova EV. Anti-glomerular basement membrane antibody disease with mild kidney failure and without progression of lung pathology: case report. Medical Radiology and Radiation Safety. 2022;67(4):96-100. DOI: 10.33266/1024-6177-2022-67-4-96-100
References
1. Jennette J.C., Nickeleit V. Anti-Glomerular Basement Membrane Glomerulonephritis and Goodpasture Syndrome. Heptinstall’s Pathology of the Kidney. Eds. Jennette J.C., Silva F.G., Olson J.L., et al. Philadelphia, Wolters Kluwer, 2015. P. 657–684.
2. Pusey C.D. Anti-Glomerular Basement Membrane Disease. Kidney Int. 2003;64:1535–1550.
3. Fischer E.G., Lager D.J. Anti-Glomerular Basement Membrane Glomerulonephritis: a Morphologic Study of 80 Cases. Am. J. Clin. Pathol. 2006;125:445–450.
4. Silvariño R., Noboa O., Cervera R. Anti-Glomerular Basement Membrane Antibodies. Isr. Med. Assoc. J. 2014;16:727–732.
5. Salama A.D., Levy J.B., Lightstone L., Pusey C.D. Goodpasture's Disease. Lancet. 2001;358:917–920.
6. Nagano, et al. Case Report: Anti-Glomerular Basement Membrane Antibody Disease with Normal Renal Function. BMC Nephrology. 2015;16:185.
7. Savage C.O., Pusey C.D., Bowman C., Rees A.J., Lockwood C.M. Antiglomerular Basement Membrane Antibody Mediated Disease in the British Isles 1980-4. Br. Med. J. (Clin. Res. Ed.) 1986;292:301-304.
8. Cui Z., Zhao M.H., Singh A.K., Wang H.Y. Antiglomerular Basement Membrane Disease with Normal Renal Function. Kidney Int. 2007;72:1403–1408.
9. Bowley N.B., Steiner R.E., Chin W.S. The Chest X-Ray in Antiglomerular Basement Membrane Antibody Disease (Goodpasture's Syndrome). Clin. Radiol. 1979;30:419-429.
10. Sheykh Zh.V., Zakharova Ye.V., Dunayev A.P. Sistemnyye Vaskulity: Vozmozhnosti Sovremennoy Meditsinskoy Vizualizatsii = Systemic Vasculitis: the Possibilities of Modern Medical Imaging. Moscow, Kraft+ Publ., 2019. 172 p. (In Russ.) [Шейх Ж.В., Захарова Е.В., Дунаев А.П. Системные васкулиты: возможности современной медицинской визуализации. М: Крафт+, 2019. 170 с.].
11. Brant W.E., Helms C.A. Fundamentals of Diagnostic Radiology. Lippincott Williams & Wilkins, 2007. ISBN:0781765188.
12. Collard H.R., Schwarz M.I. Diffuse Alveolar Hemorrhage. Clin. Chest Med. 2004;25:583–592.
13. Hansell D.M. Small-Vessel Diseases of the Lung: CT-Pathologic Correlates. Radiology. 2002;225;3:639-653. DOI: 10.1148/radiol.2253011490.
14. Sheikh Zh.W., Safonova T.D Computed Tomography for the Diagnosis of Pulmonary Lesions in Patients with Systemic Vasculitis. Prakticheskaya pulmonologiya. 2019;2:69-74 (In Russ.) [Шейх Ж.В., Сафонова Т.Д. Компьютерная томография в диагностике легочных поражений при системных васкулитах // Практическая пульмонология. 2019. № 2. С. 69-74].
15. Primack S.L., Miller R.R., Müller N.L. Diffuse pulmonary hemorrhage: clinical, pathologic, and imaging features. AJR Am. J. Roentgenol. 1995;164;2:295-300.
16. Foster, Mary H., Basement Membranes and Autoimmune Diseases. Matrix Biology. 2017;57-58:149-168. DOI: 10.1016/j.matbio.2016.07.008.
17. Specks U. Diffuse Alveolar Hemorrhage Syndromes. Curr. Opin. Rheumatol. 2001;13:12–17.
18. Reiser M.F. Multislice CT. Springer Verlag, 2010. ISBN: 3642069681.
19. Levy J.B., Turner A.N., Rees A.J., Pusey C.D. Long-Term Outcome of Anti-Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression. Ann. Intern. Med. 2001;134:1033–1042.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors
Article received: 28.03.2022. Accepted for publication: 23.05.2022